UY35027A - Proteínas del dominio de soporte basadas en fibronectina que se fijan a miostatina - Google Patents

Proteínas del dominio de soporte basadas en fibronectina que se fijan a miostatina

Info

Publication number
UY35027A
UY35027A UY0001035027A UY35027A UY35027A UY 35027 A UY35027 A UY 35027A UY 0001035027 A UY0001035027 A UY 0001035027A UY 35027 A UY35027 A UY 35027A UY 35027 A UY35027 A UY 35027A
Authority
UY
Uruguay
Prior art keywords
proteins
myostatin
based support
fibronectine
relates
Prior art date
Application number
UY0001035027A
Other languages
English (en)
Inventor
Engle Linda
Sharon T Cload
Lipovsek Dasa
Madireddi Malavi
Ginger Chao Rakestraw
Joanna F Swain
Zhao Wenjun
Original Assignee
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49253416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35027(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Publication of UY35027A publication Critical patent/UY35027A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)

Abstract

La presente invención se refiere a proteínas del dominio de soporte basadas en fibronectina que se fijan a miostatina. La invención también se refiere al uso de estas proteínas en aplicaciones terapéuticas para tratar distrofia muscular, caquexia, sarcopenia, osteoartritis, osteoporosis, diabetes, obesidad, EPOC, nefropatía crónica, insuficiencia cardíaca, infarto de miocardio y fibrosis. La invención también se refiere a células que comprenden esas proteínas, polinucleótidos que codifican esas proteínas o fragmentos de estas, y a vectores que comprenden los polinucleótidos que codifican las proteínas.
UY0001035027A 2012-09-13 2013-09-12 Proteínas del dominio de soporte basadas en fibronectina que se fijan a miostatina UY35027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700697P 2012-09-13 2012-09-13
US201361780005P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
UY35027A true UY35027A (es) 2014-03-31

Family

ID=49253416

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035027A UY35027A (es) 2012-09-13 2013-09-12 Proteínas del dominio de soporte basadas en fibronectina que se fijan a miostatina

Country Status (33)

Country Link
US (8) US8853154B2 (es)
EP (4) EP2895503B1 (es)
JP (2) JP6346895B2 (es)
KR (3) KR102424590B1 (es)
CN (2) CN108409856B (es)
AU (2) AU2013315482B2 (es)
BR (1) BR112015005466B1 (es)
CA (1) CA2884730C (es)
CL (1) CL2015000500A1 (es)
DK (3) DK3564258T3 (es)
EA (1) EA033536B1 (es)
ES (2) ES2727453T3 (es)
FI (1) FI3835310T3 (es)
HK (1) HK1212717A1 (es)
HR (2) HRP20190845T1 (es)
HU (2) HUE043482T2 (es)
IL (3) IL270110B (es)
LT (3) LT2895503T (es)
MX (2) MX366666B (es)
MY (2) MY172863A (es)
NZ (1) NZ628446A (es)
PE (1) PE20150954A1 (es)
PH (1) PH12015500397B1 (es)
PL (3) PL3835310T3 (es)
PT (3) PT3835310T (es)
RS (3) RS62009B1 (es)
SG (3) SG10201913685YA (es)
SI (2) SI3564258T1 (es)
TN (1) TN2015000086A1 (es)
TW (2) TWI694085B (es)
UY (1) UY35027A (es)
WO (1) WO2014043344A1 (es)
ZA (1) ZA201501457B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
EP3415528B1 (en) * 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
MX371442B (es) 2012-08-24 2020-01-30 Chugai Pharmaceutical Co Ltd VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
ES2727453T3 (es) 2012-09-13 2019-10-16 Bristol Myers Squibb Co Proteínas de dominio de armazón a base de fibronectina que se unen a miostatina
AU2014209178B2 (en) 2013-01-25 2018-11-08 Takeda Pharmaceutical Company Limited Follistatin in treating Duchenne muscular dystrophy
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
ES2689372T3 (es) 2013-02-06 2018-11-13 Bristol-Myers Squibb Company Proteínas de dominio de fibronectina tipo III con solubilidad mejorada
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
LT2981822T (lt) 2013-05-06 2020-12-28 Scholar Rock, Inc. Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
JP6591437B2 (ja) 2014-03-20 2019-10-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン
MX371403B (es) 2014-03-20 2020-01-29 Bristol Myers Squibb Co Moleculas de andamiaje a base de fibronectina estabilizada.
US10016394B2 (en) 2014-04-16 2018-07-10 The Scripps Research Institute PPARG modulators for treatment of osteoporosis
US11072681B2 (en) 2014-07-28 2021-07-27 The Regents Of The University Of California Compositions and methods of making polymerizing nucleic acids
US10980744B2 (en) 2014-08-08 2021-04-20 The Regents Of The University Of California High density peptide polymers
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
DK3221346T3 (da) 2014-11-21 2020-10-12 Bristol Myers Squibb Co Antistoffer omfattende modificerede konstante områder af tungkæden
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
EP3224277B1 (en) 2014-11-25 2020-08-26 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
AU2015369683C1 (en) 2014-12-23 2024-06-20 Bristol-Myers Squibb Company Antibodies to TIGIT
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
US10993993B2 (en) * 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
HRP20230060T1 (hr) 2015-05-29 2023-03-17 Bristol-Myers Squibb Company Antitijela protiv ox40 i njihova primjena
BR112017028353A2 (pt) 2015-06-29 2018-09-04 The Rockfeller University anticorpos para cd40 com atividade agonista melhorada
US20180228925A1 (en) * 2015-08-28 2018-08-16 University Of Massachusetts Quantifying Net Axonal Transport in Motor Neuron Pathologies
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
EP3423489A1 (en) 2016-03-04 2019-01-09 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
US20190284293A1 (en) 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
RU2613420C1 (ru) * 2016-04-13 2017-03-16 Сергей Михайлович Юдин Рекомбинантный белок Мио-ГСД, способ его получения, инъекционный препарат для повышения мышечной массы сельскохозяйственных животных, птицы и животных семейства псовых, а также способ использования препарата
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
KR102397783B1 (ko) 2016-06-01 2022-05-12 브리스톨-마이어스 스큅 컴퍼니 Pd-l1 결합 폴리펩티드에 의한 pet 영상화
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
RU2757394C2 (ru) * 2016-08-03 2021-10-14 Нексткьюр, Инк. Композиции и способы для модуляции передачи сигнала lair
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
CN110234334B (zh) * 2016-12-05 2024-02-06 大塚制药株式会社 肌肉萎缩抑制组合物
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TW201842929A (zh) * 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
CN116333129A (zh) 2017-05-25 2023-06-27 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
KR20200058322A (ko) 2018-01-25 2020-05-27 아이-맵 바이오파마 유에스 리미티드 항-pd-l1 항체 및 il-7 융합체
CN108593615A (zh) * 2018-05-02 2018-09-28 浠思（上海）生物技术有限公司 利用htrf一步法筛选pd1/pd-l1阻断剂的方法
JP7051656B2 (ja) 2018-09-28 2022-04-11 三菱重工コンプレッサ株式会社 タービンステータ、蒸気タービン、及び仕切板
WO2020102501A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
JP2023516459A (ja) 2020-03-09 2023-04-19 ブリストル－マイヤーズ スクイブ カンパニー 増強されたアゴニスト活性を有するｃｄ４０に対する抗体
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
US11566346B2 (en) 2020-06-25 2023-01-31 Philip David Rodley Protein scaffold
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5770697A (en) 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5641648A (en) 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5792742A (en) 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
WO2002081494A1 (en) 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
WO1994017097A1 (en) 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
RU2233878C2 (ru) 1997-01-21 2004-08-10 Дзе Дженерал Хоспитал Корпорейшн Способ отбора желательного белка и нуклеиновой кислоты, средства для его осуществления
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
WO1999056768A1 (en) 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2329959T5 (es) 1998-12-10 2013-12-18 Bristol-Myers Squibb Company Armazones de proteína para miméticos de anticuerpo y otras proteínas de unión
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP2003528632A (ja) 2000-03-31 2003-09-30 インスティティ・パスツール 血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
EP2385067A1 (en) 2000-07-11 2011-11-09 Research Corporation Technologies, Inc. Artificial antibody polypeptides
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
CA2443332A1 (en) 2001-04-04 2002-10-17 University Of Rochester .alpha..nu..beta.3 integrin-binding polypeptide monobodies and their use
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
ES2466716T3 (es) 2002-11-08 2014-06-11 Ablynx N.V. Anticuerpos de un solo dominio estabilizados
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005094446A2 (en) 2004-03-23 2005-10-13 Eli Lilly And Company Anti-myostatin antibodies
WO2005118646A2 (en) 2004-04-26 2005-12-15 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
KR20070083941A (ko) 2004-10-04 2007-08-24 큐엘티 유에스에이, 인코포레이티드 중합체 전달 조성을 갖는 눈 전달
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
CA2605723A1 (en) 2005-04-25 2006-11-02 Pfizer Inc. Antibodies to myostatin
CN101379086B (zh) 2005-08-19 2013-07-17 惠氏公司 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
JP5052517B2 (ja) 2005-10-06 2012-10-17 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
JP2009518422A (ja) 2005-12-06 2009-05-07 アムジェン インコーポレイテッド ミオスタチン・アンタゴニストの使用
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
AU2007292555B2 (en) 2006-09-05 2012-05-31 Eli Lilly And Company Anti-myostatin antibodies
WO2008031098A1 (en) 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
AU2008287426B2 (en) 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
JP2010538972A (ja) 2007-08-20 2010-12-16 ブリストル−マイヤーズ スクイブ カンパニー 転移性癌の処置のためのｖｅｇｆｒ−２阻害剤の使用
KR100857861B1 (ko) 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
BRPI0818810A2 (pt) 2007-10-31 2014-10-29 Medimmune Llc Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável.
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2217274A1 (en) 2007-11-28 2010-08-18 Bristol-Myers Squibb Company Combination vegfr2 therapy with mtor inhibitors
CA2709994A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Non-antibody scaffold protein fusions phage display via fusion to pix of m13 phage
WO2009083804A2 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
JP2011517314A (ja) 2008-02-14 2011-06-02 ブリストル−マイヤーズ スクイブ カンパニー Ｅｇｆｒに結合する操作されたタンパク質に基づく標的化された治療薬
EP2439212B1 (en) 2008-05-02 2016-12-21 Novartis AG Improved fibronectin-based binding molecules and uses thereof
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
AU2009308935B2 (en) 2008-10-31 2015-02-26 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
AU2009327189B2 (en) 2008-12-16 2012-09-06 Novartis Ag Yeast display systems
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
EP2396000A1 (en) 2009-02-11 2011-12-21 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
WO2011020033A2 (en) 2009-08-13 2011-02-17 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
ES2691717T3 (es) 2009-10-30 2018-11-28 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
CA2788972A1 (en) 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
AU2011218243A1 (en) 2010-02-18 2012-10-04 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
DK2558491T3 (en) 2010-04-13 2018-10-15 Bristol Myers Squibb Co Fibronectin-based Scaffold domain proteins that bind PCSK9
EP2558495B1 (en) 2010-04-13 2019-07-17 MedImmune, LLC Trail r2-specific multimeric scaffolds
KR101863033B1 (ko) 2010-04-30 2018-06-01 얀센 바이오테크 인코포레이티드 안정화된 파이브로넥틴 도메인 조성물, 방법 및 용도
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JP6092773B2 (ja) 2010-07-30 2017-03-08 ノバルティス アーゲー フィブロネクチンクレードル分子及びそのライブラリ
SG187867A1 (en) 2010-08-16 2013-03-28 Amgen Inc Antibodies that bind myostatin, compositions and methods
US9260496B2 (en) * 2010-12-22 2016-02-16 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
ES2848531T3 (es) 2011-05-17 2021-08-10 Bristol Myers Squibb Co Métodos mejorados para la selección de proteínas de unión
IL277891B2 (en) 2011-09-27 2024-01-01 Janssen Biotech Inc Protein scaffolds based on type III fibronectin repeats with alternative binding surfaces
BR112014031028A2 (pt) 2012-06-11 2017-08-15 Amgen Inc Proteína de ligação ao antígeno isolado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para produzir uma proteína de ligação ao antígeno, composição, método para reduzir ou bloquear a atividade de miostatina, activin a ou gdf-11, método para aumentar a firmeza da massa muscular ou aumentar a proporção da firmeza da massa muscular para massa adiposo em um indivíduo necessitado do referido tratamento, método para tratar ou prevenir uma doença prejudicial do músculo em um indivíduo sofrendo do referido distúrbio e anticorpo receptor duplo antagonista
JP6433889B2 (ja) 2012-06-15 2018-12-05 ファイザー・インク Ｇｄｆ−８に対する改善された拮抗抗体およびその使用
ES2727453T3 (es) 2012-09-13 2019-10-16 Bristol Myers Squibb Co Proteínas de dominio de armazón a base de fibronectina que se unen a miostatina
TW201842929A (zh) 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物

Also Published As

Publication number Publication date
SG10201701970TA (en) 2017-05-30
PT3835310T (pt) 2024-05-20
EP4397675A2 (en) 2024-07-10
TW201416376A (zh) 2014-05-01
US20140107020A1 (en) 2014-04-17
ES2727453T3 (es) 2019-10-16
AU2013315482B2 (en) 2018-03-15
KR20220107082A (ko) 2022-08-01
RS58801B1 (sr) 2019-07-31
US10406212B2 (en) 2019-09-10
FI3835310T3 (fi) 2024-05-31
BR112015005466A2 (pt) 2017-08-08
MY172863A (en) 2019-12-13
EP2895503A1 (en) 2015-07-22
TN2015000086A1 (en) 2016-06-29
ES2879387T3 (es) 2021-11-22
US8933199B2 (en) 2015-01-13
PL3835310T3 (pl) 2024-06-03
TWI633117B (zh) 2018-08-21
PL3564258T3 (pl) 2021-10-25
CN108409856B (zh) 2022-03-04
SG10201913685YA (en) 2020-03-30
RS62009B1 (sr) 2021-07-30
CL2015000500A1 (es) 2015-07-31
ZA201501457B (en) 2021-09-29
LT2895503T (lt) 2019-07-25
MX2015002894A (es) 2015-06-03
SI2895503T1 (sl) 2019-08-30
KR102424590B1 (ko) 2022-07-27
US20150231211A1 (en) 2015-08-20
IL237559A0 (en) 2015-04-30
PH12015500397A1 (en) 2015-04-27
US10245302B2 (en) 2019-04-02
PT2895503T (pt) 2019-06-03
DK3835310T3 (da) 2024-06-03
SI3564258T1 (sl) 2021-07-30
CN108409856A (zh) 2018-08-17
IL294314A (en) 2022-08-01
US11813315B2 (en) 2023-11-14
PL2895503T3 (pl) 2019-09-30
EP3564258B1 (en) 2021-04-28
PE20150954A1 (es) 2015-06-20
US20170354718A1 (en) 2017-12-14
KR20150054938A (ko) 2015-05-20
RS65556B1 (sr) 2024-06-28
KR102187714B1 (ko) 2020-12-07
EA201590543A1 (ru) 2015-06-30
EP2895503B1 (en) 2019-03-27
US20140309163A1 (en) 2014-10-16
PH12015500397B1 (en) 2015-04-27
US20190307855A1 (en) 2019-10-10
HRP20210990T1 (hr) 2021-09-17
EP3835310B1 (en) 2024-03-20
WO2014043344A1 (en) 2014-03-20
EP3564258A1 (en) 2019-11-06
KR20200138435A (ko) 2020-12-09
AU2018201273A1 (en) 2018-03-15
US8853154B2 (en) 2014-10-07
TWI694085B (zh) 2020-05-21
CN104768969B (zh) 2021-04-16
JP2018183138A (ja) 2018-11-22
US9493546B2 (en) 2016-11-15
NZ628446A (en) 2017-06-30
TW201823269A (zh) 2018-07-01
JP6793680B2 (ja) 2020-12-02
EA033536B1 (ru) 2019-10-31
US8993265B2 (en) 2015-03-31
AU2018201273B2 (en) 2020-04-09
CA2884730A1 (en) 2014-03-20
DK3564258T3 (da) 2021-06-21
AU2013315482A1 (en) 2015-03-12
BR112015005466B1 (pt) 2023-04-11
MX2019008391A (es) 2019-09-09
HUE054699T2 (hu) 2021-09-28
IL237559B (en) 2019-10-31
JP6346895B2 (ja) 2018-06-20
US20170088602A1 (en) 2017-03-30
DK2895503T3 (da) 2019-05-27
CA2884730C (en) 2023-07-04
PT3564258T (pt) 2021-06-30
US9662373B2 (en) 2017-05-30
LT3835310T (lt) 2024-04-25
IL270110A (es) 2019-12-31
JP2015530390A (ja) 2015-10-15
HK1212717A1 (zh) 2016-06-17
SG11201501741YA (en) 2015-04-29
US20140105896A1 (en) 2014-04-17
CN104768969A (zh) 2015-07-08
HUE043482T2 (hu) 2019-08-28
EP3835310A1 (en) 2021-06-16
IL270110B (en) 2022-08-01
MX366666B (es) 2019-07-19
US20150072919A1 (en) 2015-03-12
HRP20190845T1 (hr) 2019-08-09
LT3564258T (lt) 2021-08-25
MY189682A (en) 2022-02-25

Similar Documents

Publication Publication Date Title
UY35027A (es) Proteínas del dominio de soporte basadas en fibronectina que se fijan a miostatina
CY1122539T1 (el) Αναλογα γλυκαγονης
AR125268A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
CY1122107T1 (el) Τροποποιημενες πρωτεϊνες δεσμευσης οι οποιες αναστελλουν την αλληλεπιδραση υποδοχεα vegf-a
CY1122399T1 (el) Αγωνιστικοι παραγοντες δεσμευσης του υποδοχεα tnf
CY1121462T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
EA201600338A1 (ru) Биспецифическая связывающая молекула, связывающаяся с vegf и ang2
MX2015014538A (es) Moleculas de union a antigenos trimericas.
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
EA201590294A1 (ru) Аналоги глюкагона
WO2016094873A3 (en) Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
CL2015001353A1 (es) Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.
CL2014003465A1 (es) Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
AR092076A1 (es) Proteinas homodimericas
EA201591839A1 (ru) Терапевтические пептиды
CO6382161A2 (es) Moleculas biespecificas de union a egfr/igfir
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
CL2013002044A1 (es) Anticuerpo que une il-17a humano e il-17f humano; secuencia de adn que lo codifica; vector; celula huesped; proceso de produccion; composicion farmaceutica que lo comprende; y su uso para el tratamiento profilaxis de un trastorno patologico mediado por il-17a y/o il-17f.
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
EA201492067A1 (ru) Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20230529